Lynparza (olaparib) for the Treatment of BRCA-mutated Advanced Ovarian Cancer - Clinical Trials Arena
Frontiers | PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials | Oncology
LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative Metastatic Breast Cancer
Olaparib Maintenance Therapy Delays Ovarian Cancer Progression - NCI
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
Clinical Trials of PARP inhibitors in ovarian cancer | Download Table
PARP inhibitors: Choosing what to use in epithelial ovarian cancer
JCM | Free Full-Text | Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study | HTML
Platinum-Sensitive Recurrent Disease - PARPi in Ovarian Cancer - Module - PARPi in Ovarian Cancer - Oncology - Clinical Care Options
Efficacy of LYNPARZA® (olaparib) for Maintenance of BRCAm Advanced Ovarian Cancer
Breakthrough from PAOLA1 GINECO/ENgOT-ov25 trial
Blockbuster status competition intensifying for PARP inhibitors - Pharmaceutical Technology
Olaparib for Ovarian Cancer Clinical Trial | Power
SOLO-1 Phase 3 Trial Demonstrates LYNPARZA® (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer | Business Wire
Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design | Future Oncology
Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evid | OTT
Clinical trials results for PARP Inhibitors in ovarian cancer. | Download Table
PAOLA-1 Phase 3 Trial – LYNPARZA® (olaparib) + Bevacizumab for Advanced Ovarian Cancer
Lynparza (olaparib) for the Treatment of BRCA-mutated Advanced Ovarian Cancer - Clinical Trials Arena
A trial of olaparib for ovarian cancer that has come back (MOLTO) | Cancer Research UK
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy | British Journal of Cancer
SOLO-1 Phase III trial demonstrates Lynparza maintenance therapy cut risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated ovarian cancer
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial - ScienceDirect
Platinum-Sensitive Recurrent Disease - PARPi in Ovarian Cancer - Module - PARPi in Ovarian Cancer - Oncology - Clinical Care Options
